Small molecule peptide with analgesic effect and specific antibody thereof

An antibody and active technology, applied in the field of small molecule peptides and their specific antibodies, can solve problems such as toxic and side effects

Pending Publication Date: 2021-10-22
PEKING UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Early studies have shown that agonists and blockers of TRPV1 are effective as analgesics, but both have significant toxic side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Small molecule peptide with analgesic effect and specific antibody thereof
  • Small molecule peptide with analgesic effect and specific antibody thereof
  • Small molecule peptide with analgesic effect and specific antibody thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0067] Example 1, the discovery of functional fragments—Nogo-Aaa 846-861

[0068] The human Nogo-A protein has 1192 amino acid residues (SEQ ID No.1), using the method of bioinformatics, by analyzing the structural characteristics of the human Nogo-A protein such as spatial structure, hydrophilicity, flexibility The bioinformatics analysis of the protein secondary structure, antigenicity and surface exposure probability revealed two potential new functional domains, namely Nogo-Aaa435-451 and Nogo-Aaa 872-888. At the same time, by comparing the amino acid sequences (SEQ ID No.2) of human-derived and rat-derived Nogo-A proteins, two potential rat sequences of new functional domains in bioinformatics analysis were found: Nogo-Aaa 415 -430 and Nogo-Aaa 846-861. The specific sequence of the functional fragment is shown in Table 1.

[0069] Table 1

[0070]

Embodiment 2

[0071] Example 2. Functional verification of Nogo-Aaa 846-861 fragment and its antagonistic peptide and specific antibody

[0072] 1. Preparation of Experiment-Related Peptides

[0073] Competitive antagonistic peptide 846-861PE of the Nogo-Aaa 846-861 fragment: Synthesized by Gil Biochemical (Shanghai) Co., Ltd., the sequence is PTFVSAKDDSPKLAKE, dissolved in sterile saline according to the purity, and the final concentration is 1 μg / μl. Scramble1 (control peptide 1): Synthesized by Jill Biochemical (Shanghai) Co., Ltd., the sequence is KDKESLDTPVAFAKS, dissolved in sterile saline according to the purity, and the final concentration is 1 μg / μl.

[0074] Nogo-Aaa 415-430 competitive antagonistic peptide 415-430PE: Synthesized by Jill Biochemical (Shanghai) Co., Ltd., the sequence is KDSEGRNEDASFPSTP, dissolved in sterile saline according to the purity, and the final concentration is 1 μg / μl. Scramble2 (control peptide 2): Synthesized by Gill Biochemical (Shanghai) Co., Ltd., ...

Embodiment 3

[0130] Example 3, Nogo-Aaa 846-861 fragments and their antagonistic peptides and specific antibodies regulate TRPV1

[0131] 1. The regulatory effect of antagonistic peptides on TRPV1

[0132] Experimental animals: adult male SD rats (Sprague-Dawley Rat, body weight 150-200 g, 6-8 weeks old).

[0133] Refer to the previous method for subarachnoid catheterization.

[0134] Rats underwent subarachnoid catheterization for 5 days to measure the basic pain threshold (except for abnormal rats). The rats were randomly divided into two groups, and then subarachnoid injections of 10 μg of competitive antagonistic peptide 846-861PE and As a control peptide Scramble 1, Western Blot method was used to detect the change of TRPV1 protein (TRPV-1, sc-12498, Santa Cruz Biotechnology) content in the basal state.

[0135] Rats underwent subarachnoid catheterization for 5 days to measure the basic pain threshold (except for abnormal rats). The rats were randomly divided into two groups, and th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a small molecule peptide with an analgesic effect and a specific antibody thereof. The invention provides a functional fragment which is an amino acid fragment as shown in the 872-888 site from the N terminal of SEQ ID No. 1 or an amino acid fragment as shown in the 846-861 site from the N terminal of SEQ ID No. 2. A competitive antagonistic peptide and a neutralizing antibody are also designed by aiming at the functional fragment. Experiments prove that both the competitive antagonistic peptide and the neutralizing antibody have the analgesic function, but do not influence the basic pain threshold; meanwhile, the functional fragment can inhibit the growth of neuronal axons, and the antibody can reverse the inhibition effect of the functional fragment on the growth of neuronal axons. A new thought is provided for research and treatment of chronic pain.

Description

technical field [0001] The invention relates to a small molecule peptide with analgesic effect and its specific antibody. Background technique [0002] Pain is a complex physiological and psychological activity. In 2016, WilliamsAC et al. corrected the definition of pain as follows: Pain is a painful experience associated with actual or potential tissue damage, involving multidimensional components of sensation, emotion, cognition and society . Pain includes physiological pain (i.e. acute pain) and pathological pain (i.e. chronic pain). Physiological pain, as a defense mechanism of the body, causes the body to produce a series of defensive protective responses, prompting the organism to escape from the source of pain; but pathological pain State, such as inflammation or nerve damage, will increase the efficiency of pain transmission, resulting in long-term severe pain. According to relevant epidemiological surveys, the prevalence of chronic pain in the world population has...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K14/475C07K16/22A61K38/18A61K39/395A61P29/00A61P25/00
CPCC07K14/475C07K16/22A61P29/00A61P25/00C07K2317/76A61K38/00A61K2039/505
Inventor 王君刘怀存
Owner PEKING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap